Safety and efficacy of COVID-19 vaccines in pregnant and lactating women: a comprehensive review
Authors:
- Sumel AshiqueSASumel Ashique
- Mohini MondalMMMohini Mondal
- Sadique HussainSHSadique Hussain
- Anas IslamAIAnas Islam
- Mohd TariqMTMohd Tariq
- Dinesh Kumar ChellappanDCDinesh Kumar Chellappan
- Sabina YasminSYSabina Yasmin
- Tabarak MalikTabarak Malik
- Juberahamad Rajjak AttarJAJuberahamad Rajjak Attar
- Yousuf AnsariYousuf Ansari
- 21 April 2026
- journal article
- review article
- Published by Springer Nature in Inflammopharmacology
- Vol. 34 (5) , 2873-2888
Abstract
Breastfeeding plays a critical role in providing essential nutrients and antibodies that enhance the health of new-borns and infants, supporting their immune systems and overall growth and development. Healthcare professionals, universally recommend breastfeeding for the first six months of an infant’s life, in conjunction with an appropriate complementary diet. However, the COVID-19 pandemic has understandably raised concerns among lactating mothers and pregnant women regarding the risks of infection and vaccine safety. Therefore, it is essential to carefully evaluate the potential dangers of COVID-19 transmission within this vulnerable population especially when considering vaccination for pregnant and breastfeeding women. Encouragingly, the United States Food and Drug Administration has granted approval for the use of two COVID-19 vaccines namely, Pfizer-BioNTech COVID-19 and Moderna COVID-19 to contain the spread of the COVID-19 virus. Both vaccines have been approved for administration in pregnant and breastfeeding women, providing much-needed reassurance to those with concerns about vaccine safety. It is important to recognize that the benefits of vaccination for both the mother and the infant far outweigh the risks associated with COVID-19 infection. Therefore, lactating mothers should view vaccination as a vital measure to protect themselves and their infants from the virus. In addition to elaborating on the successes of safety and effectiveness, this review is unique that it also includes current and newly updated evidence published between 2020 and 2025, comprehensively discussing on several newer vaccine platforms together with recent viral variants. Furthermore, it synthesizes information on the transfer of transplacental and a breast-milk antibody that outlines a clear evidence-gap that may direct further research within pregnant and lactating populations. Graphical abstract The alternative text for this image may have been generated using AI.Keywords
Funding Information
- Deanship of Scientific Research, King Khalid University
This publication has 100 references indexed in Scilit:
- mRNA COVID‐19 vaccination early in pregnancy and the risk of spontaneous abortion in an international pregnancy registryPharmacoepidemiology and Drug Safety, 2023
- Association of COVID-19 Vaccination in Pregnancy With Adverse Peripartum OutcomesJAMA, 2022
- SARS-CoV-2–Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding WomenJAMA, 2021
- Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating WomenJAMA, 2021
- Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19JAMA, 2021
- No Populations Left Behind: Vaccine Hesitancy and Equitable Diffusion of Effective COVID-19 VaccinesJournal of General Internal Medicine, 2021
- Involving Pregnant Individuals in Clinical Research on COVID-19 VaccinesJAMA, 2021
- COVID-19 Vaccination in Pregnant and Lactating WomenJAMA, 2021
- Evaluation for SARS-CoV-2 in Breast Milk From 18 Infected WomenJAMA, 2020
- Vaccine responses in newbornsSeminars in Immunopathology, 2017